BFM
APLS

Boothbay Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History

Boothbay Fund Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.38M Buy
183,522
+162,107
+757% +$3.49M 0.1% 208
2025
Q4 		$538K Sell
21,415
-157,811
-88% -$3.7M 0.01% 1094
2025
Q3 		$4.06M Buy
179,226
+156,229
+679% +$3.64M 0.06% 366
2025
Q2 		$398K Hold
22,997
– – 0.01% 1000
2025
Q1 		$503K Buy
+22,997
New +$635K 0.01% 850
2024
Q2 		– Sell
-24,825
Closed -$1.46M – 1503
2024
Q1 		$1.46M Buy
24,825
+12,169
+96% +$776K 0.03% 614
2023
Q4 		$758K Buy
12,656
+4,806
+61% +$244K 0.02% 816
2023
Q3 		$299K Sell
7,850
-19,344
-71% -$850K 0.01% 1249
2023
Q2 		$2.48M Buy
27,194
+6,136
+29% +$529K 0.05% 473
2023
Q1 		$1.39M Buy
+21,058
New +$1.22M 0.03% 842
2022
Q3 		– Sell
-5,065
Closed -$300K – 2223
2022
Q2 		$229K Buy
+5,065
New +$231K 0.01% 1644
2021
Q4 		– Sell
-34,671
Closed -$1.36M – 1842
2021
Q3 		$1.14M Buy
+34,671
New +$1.95M 0.03% 699
2020
Q2 		– Sell
-9,448
Closed -$253K – 952
2020
Q1 		$253K Buy
+9,448
New +$335K 0.02% 610
2019
Q1 		– Sell
-26,000
Closed -$343K – 741
2018
Q4 		$343K Buy
+26,000
New +$399K 0.05% 353

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Boothbay Fund Management's APLS Position: Q1 2026 in Review

Boothbay Fund Management increased its Apellis Pharmaceuticals (APLS) stake by 757% in Q1 2026, buying an estimated $3.49M and bringing the position to 183,522 shares worth $7.38M. The position accounts for 0.1% of the portfolio, ranked #208.

Boothbay Fund Management first reported a position in APLS in Q4 2018 and has held it in 14 quarters since. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Boothbay Fund Management held 183,522 shares of Apellis Pharmaceuticals worth $7.38M as of Q1 2026.
  • Boothbay Fund Management bought 162,107 Apellis Pharmaceuticals shares in Q1 2026, an estimated $3.49M.
  • Apellis Pharmaceuticals made up 0.1% of Boothbay Fund Management's portfolio in Q1 2026, its #208 holding.
  • Boothbay Fund Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and has held it in 14 quarters since.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.